ストックスクリーナーアプリを入手
3.19
2.90%
0.09
前日終値:
$3.10
開ける：
$3.1
24時間の取引高:
94,886
Relative Volume:
1.91
時価総額：
$83.21M
収益：
$6.21M
当期純損益:
$-19.92M
株価収益率:
-3.0381
EPS:
-1.05
ネットキャッシュフロー:
$-16.76M
1週間 パフォーマンス:
+8.14%
1か月 パフォーマンス:
+8.50%
6か月 パフォーマンス:
+11.93%
1年 パフォーマンス:
+22.48%
1日の値動き範囲:
$3.10
$3.305
1週間の範囲:
$2.60
$3.305
52週間の値動き範囲:
$1.81
$3.42
InspireMD Inc. Stock (NSPR) Company Profile
NSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
3.19 | 83.21M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2016-01-07 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 開始されました | Oppenheimer | Outperform |
InspireMD Inc. (NSPR) 最新ニュース
InspireMD and NAMSA to begin study of carotid stent system for TCAR procedures - Yahoo
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com - Defense World
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal - GlobeNewswire
InspireMD And NAMSA To Partner On CGuardians II Pivotal Clinical Trial Of The CGuard Prime 80 Cm Carotid Stent System For Use In TCAR Procedures - Marketscreener.com
Major Clinical Trial Alert: InspireMD's Revolutionary TCAR Stent Targets $1B+ Market - StockTitan
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Key Executive Compensation Alert: InspireMD Awards Strategic Stock Package to New Hire - StockTitan
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 86%, even after 10% gain this past week - Simply Wall St
Compliance Issues And Stock Developments Hit Nasdaq Companies - Evrim Ağacı
InspireMD Awards Strategic Employee Stock Grants to Accelerate Growth, Adds 9 New Hires - StockTitan
StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD : Breakthrough device in clinical trials aims to prevent strokes -January 20, 2025 at 07:59 am EST - Marketscreener.com
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation - Yahoo Finance
InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com - MarketBeat
InspireMD (NYSE:NSPR) Now Covered by StockNews.com - Defense World
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
InspireMD, Inc. CFO Craig Shore to Retire, Company Initiates Search for SuccessorDecember 12, 2024 - Defense World
NSPRInspireMD, Inc. Latest Stock News & Market Updates - StockTitan
Medical device company kicks off search for next CFO - The Business Journals
InspireMD CFO Craig Shore to retire, successor search underway - Investing.com India
InspireMD CFO Retirement Amid Strategic Transition - TipRanks
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 - GlobeNewswire
InspireMD CFO to Retire After 15 Years Amid Crucial FDA Approval Timeline for Stroke Prevention Device - StockTitan
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study - MSN
Lake Street Initiates Coverage of InspireMD (NSPR) with Buy Recommendation - MSN
InspireMD Announces First Patient Enrolled in CGUARDIANS II Pivotal Study - Defense World
Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures - Marketscreener.com
InspireMD Advances CGuard Prime with New Clinical Trial - TipRanks
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) - GlobeNewswire
InspireMD Launches Pivotal CGUARDIANS II Trial for Revolutionary Carotid Stent System - StockTitan
Head to Head Contrast: Penumbra (NYSE:PEN) vs. InspireMD (NYSE:NSPR) - Defense World
InspireMD adds medtech veteran Scott Ward to its board By Investing.com - Investing.com South Africa
InspireMD appoints Scott R. Ward to its Board - Medical Buyer
InspireMD Appoints Scott R. Ward to Board of Directors - Defense World
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors - Marketscreener.com
InspireMD adds medtech veteran Scott Ward to its board - Investing.com
InspireMD Strengthens Leadership with Scott R. Ward Appointment - TipRanks
InspireMD Announces Appointment of Accomplished Medical - GlobeNewswire
InspireMD Strengthens Board with Ex-Medtronic Executive Ahead of CGuard Prime FDA Decision | NSPR Stock News - StockTitan
InspireMD Inc. (NSPR) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
0.10%
大文字化:
|
ボリューム (24 時間):